1 / 18

How Drug Benefits Affect Pharmaceutical and Medical Use Geoffrey Joyce

How Drug Benefits Affect Pharmaceutical and Medical Use Geoffrey Joyce. Rising Expenditures on Prescription Drugs. Drug spending increasing rapidly New drugs and higher prices Increased insurance coverage Aging population Earlier diagnosis Increased marketing and advertising

ori-bridges
Télécharger la présentation

How Drug Benefits Affect Pharmaceutical and Medical Use Geoffrey Joyce

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. How Drug Benefits Affect Pharmaceutical and Medical UseGeoffrey Joyce

  2. Rising Expenditures on Prescription Drugs • Drug spending increasing rapidly • New drugs and higher prices • Increased insurance coverage • Aging population • Earlier diagnosis • Increased marketing and advertising • Drug spending about 10% of total expenditures • Higher percentage for non-elderly

  3. Health Plans Face Largest Increasesin Pharmaceutical Spending % Annual Increase 1990–98 Private health plans 18% Patients 4% Source: C. Copeland, EBRI Notes (September, 2000)

  4. Study Questions • How does benefit design affect Rx use and costs? • Do the effects of higher cost-sharing vary by drug class and patient group? • Do pharmacy benefits affect use of medical services? • What will pharmacy benefits look like over the next 3-5 years?

  5. Study Sample • Linked health care claims to health plan benefits of 30 large employers (1997-2000) • 52 health plans • 529,000 primary beneficiaries age 18-64 (960,000 person-years) • Adding data for 2001-2003

  6. Analytic Approach • Outcomes • Pharmacy spending and use (days supplied) • Inpatient and ER use • Other factors controlled for • Rx drug benefits • Medical benefits; plan type • Patient demographics • Health status (26 chronic conditions) • Area characteristics and year

  7. 1-tier $5 for all drugs 22% $165 2-tier $5 generic, $10 brand 33% $220 3-tier $5 generic, $10 preferred, $15 non-preferred brand 35% $237 Doubling Co-payments Reduces Rx Spending • $ Savings to plan • Typeof plan • % Reductionin total Rx spending • Co-payment •  $10 •  $10/20 •  $10/20/30

  8. Adding Tiers Reduces Rx Spending

  9. Drugs for Treating Chronic Conditions • Drug class Top drugs in 2000 • Antihistamines Claritin, Allegra, Zyrtec • Antiinflammatories Celebrex, Relafen, Vioxx • Antidiabetics Glucophage, Rezulin, Avandia • Antiasthmatics Singulair, Flovent • Antiulcerants Prilosec, Prevacid, Propulsid • Antihyperlipidemics Zocor, Lipitor, Pravachol • Antihypertensives Norvasc, Vasotec, Cardizem CD • Antidepressants Zoloft, Paxil, Prozac

  10. Higher Co-Pays Reduce Use; Effects Differ Across Drug Classes Chronically- ill only All members

  11. Disease-Specific Medications Decline Less Therapeutic class

  12. Impact on Medical Use For diabetes, asthma and gastric acid disorder… • Doubling co-payments led to a : • 10% increase in hospital days • 17% increase in ER visits • No significant effects for other 5 conditions Preliminary evidence • Limited information on full extent of medical plan choice

  13. Effect of Moving Prilosec (omeprazole) to 3rd Tier 1 0.9 Plan A 0.8 0.7 0.6 Proportion 0.5 of GI prescriptions 0.4 Plan B 0.3 0.2 Plan C 0.1 0 1 3 5 7 9 11 13 15 17 19 21 23 Month

  14. Assessing the Effects of Spending Caps • The tradeoff: • Lower caps decrease cost of Rx benefit, making drug coverage available to more patients • Exceeding the cap increases risk that patients will reduce medication use • Study sample: • About 1300 Medicare+Choice enrollees in one state • Exceeded annual Rx benefit cap of $750 or $1,200 in 2001 • Had resulting coverage gaps of 75-180 days

  15. Exceeding Caps Significantly Affected Medication Use Switched Used less often Used free samples % of beneficiaries using strategy

  16. Shifting More Costs to Patients Will Continue… • Survey of health plans and insurers indicate: • Continued growth in 3-tier and 4-tier benefits • Promote generics and generic-only plans • Larger co-pay differences between 1st & 3rd tiers • Tiered coinsurance • Concern over injectibles and biotech agents

  17. Summary of Findings • Cost-sharing matters (across plans, patient groups) • Doubling co-payments reduced use by 1/3rd • Largest reductions for drugs that treat symptoms • Smaller reductions in use by chronically ill • But price sensitivity raises health concerns • Spending caps affect adherence and use • 18% exceeding cap took less medication • 15% switched medications

More Related